drugset / Trial / NCT02970877

Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients

NCT02970877 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

More and more people in Canada and around the world are severely (morbidly) obese, and this is associated with a high risk for poor blood sugar control (insulin resistance, IR) and diabetes. Weight loss is often very hard to achieve for morbidly obese patients. Bariatric surgery is a very effective treatment, but it has some risks and is not available to all patients. Therefore, alternative treatments are needed. The gut bacteria (intestinal microbiome) might play a role for the development of obesity and IR. Several studies in animals have shown that transferring stool from lean mice or humans into obese animals could lead to weight loss and improve IR. One human study has confirmed this. The investigators are therefore examining, whether transfer of stool from healthy lean people into morbidly obese patients with IR will improve blood sugar control, weight, and other obesity related parameters. This will be done in a randomized controlled trial. Effects on mental health and the bacterial in the mouth related to gum disease will also be assessed. If successful, fecal transfer could be a new alternative treatment approach for morbidly obese patients or those with IR who do not have access to or do not want to undergo bariatric surgery.

Timeline

Start
2017-03-01
Primary completion
2022-06-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fecal filtrate Unknown 150 g —

Indications